Straumann stock holds in the low CHF 90s as investors await the next earnings update

Straumann stock is trading in the low CHF 90s in late August 2026, leaving investors focused on how the next set of results will compare with the company’s recent performance and valuation metrics.

Straumann Holding AG (CH0012280076) stock is trading in the low CHF 90s as of August 25, 2026, leaving investors weighing the group’s growth prospects against a double-digit billion-franc valuation. A recent quote shows Straumann shares at CHF 92.00 on the SIX Swiss Exchange, with an intraday loss of 0.97% and a 52-week range from CHF 73.02 to CHF 109.80 as of August 25, 2026 per a structured products overview. The same dataset points to a market value in the mid-teens of billions of Swiss francs, highlighting how much future earnings growth is already priced in.

Straumann stock trades below its 52-week high

Per a Swiss structured product listing that includes Straumann as an underlying, Straumann stock last changed hands at CHF 92.00 on August 25, 2026, down CHF 0.90 or 0.97% on the day, with trades executed at 2:15 p.m. local time. The same overview shows a daily low of CHF 91.94 and a daily high of CHF 93.44 on that date, giving short-term traders a clear intraday range to watch. Over a longer horizon, the 52-week low is reported at CHF 73.02 and the 52-week high at CHF 109.80, so the current CHF 92 level sits CHF 16.78 below the recent peak while remaining CHF 18.98 above the 52-week floor, underscoring that the shares are mid-range but still well above last year’s trough.

A separate Swiss market compendium lists Straumann at CHF 92.90, implying a very similar trading zone around CHF 93 as of late August 2026 and confirming that the stock continues to hover below its 52-week high. That reference also cites a market capitalization of CHF 14,813 million, placing Straumann firmly in the large-cap bracket within the medical instruments and supplies segment. For investors, the combination of a mid-range share price in the CHF 90s and a market value near CHF 15 billion underlines how valuation already anticipates continued growth in the dental implant and orthodontics markets.

Valuation metrics highlight premium expectations

The same Swiss equity overview attributes Straumann a price-to-earnings ratio for 2026 of 29.5 and a forecast dividend yield of 1.10%, based on its own estimates. In practical terms, a P/E close to 30 implies that the market is willing to pay almost thirty times expected earnings for Straumann, well above many broader indices. That premium valuation goes hand in hand with an estimated EBITDA margin of 28.33% and an EBIT margin of 21.08% in the same table, illustrating that Straumann is perceived as a structurally profitable business even after accounting for investments in growth.

Further metrics in that overview include a price-to-book ratio of 6.50 and an equity return of 16.95%, suggesting that Straumann generates double-digit returns on its capital base while trading at several times its book value. An equity ratio above 50% is also cited in the same context, pointing to a relatively solid balance sheet that can support ongoing expansion and potential acquisitions. For investors, these metrics together explain why Straumann commands a valuation premium compared with many industrial names, even as the stock currently trades below its recent 52-week high.

Dental implants and orthodontics underpin Straumann’s business

Straumann’s core business revolves around premium dental implants, prosthetics, and related biomaterials that enable dentists and oral surgeons to replace missing teeth with durable, functional solutions. Over the past years, Straumann has broadened its portfolio beyond traditional implants into orthodontic products such as clear aligner systems, digital dentistry workflows, and chairside equipment, making the group a full-service partner for dental professionals. This diversification across implants, biomaterials, and orthodontics helps Straumann capture value along the entire treatment chain, from diagnostics to final restoration.

A representative example is Straumann’s line of dental implant systems, which combine titanium or ceramic fixtures with precisely engineered abutments and customized prosthetics. These systems are designed to integrate with the patient’s jawbone and provide long-lasting stability, while digital planning tools and guided surgery kits streamline the workflow for clinicians. By pairing implants with digital scanners, planning software, and lab solutions, Straumann aims to shorten treatment times and improve outcomes compared with legacy analog workflows, a key selling point in a market where patients increasingly expect both aesthetics and function from their dental restorations.

Straumann stock price snapshot

Based on the structured product and equity overview data, Straumann stock is quoted in the CHF 92 to CHF 93 range on the SIX Swiss Exchange as of August 25, 2026, with an intraday move of roughly one percent and a 52-week span between CHF 73.02 and CHF 109.80. With a market capitalization reported at CHF 14,813 million and a forward-looking price-to-earnings ratio of 29.5, the company continues to trade at a premium to many peers, supported by estimated EBITDA and EBIT margins of 28.33% and 21.08%, respectively. For investors, the current level below the 52-week high highlights both the potential for further upside if earnings continue to grow and the sensitivity to any disappointment against these high expectations.

Read more

Structured product overview referencing Straumann

Dental implant systems as flagship products

Among Straumann’s various offerings, its branded dental implant systems form the backbone of the company’s revenue. These systems are engineered to provide osseointegration with the jawbone, minimizing healing times while maximizing long-term stability, and are used by dental professionals worldwide for both single-tooth and full-arch restorations. In many cases, the implant systems are combined with Straumann’s own prosthetic components and digital planning tools, allowing the company to tap multiple revenue streams from each treatment case.

In addition to traditional titanium implants, Straumann has also introduced ceramic and other advanced materials aimed at patients with specific aesthetic or medical requirements. These innovations respond to demand from both clinicians and patients for solutions that combine strength, biocompatibility, and visual appeal, particularly in the highly visible front-tooth region. As more patients seek implant-based solutions over removable dentures, Straumann’s ability to offer a wide range of implant types and associated prosthetics is central to sustaining its growth.

Straumann shares and investor perspective

Straumann shares are listed on the SIX Swiss Exchange, where they trade in Swiss francs and anchor the company’s status as a large-cap medical instruments and supplies name. As of August 25, 2026, the stock’s position in the CHF 90s, below a 52-week high of CHF 109.80 yet substantially above a 52-week low of CHF 73.02, reflects both the progress Straumann has made and the valuation premium investors are willing to pay for its earnings profile. For investors, the balance between high profitability metrics, such as an EBITDA margin above 28%, and a forward P/E around 29.5 will remain a key consideration as the market awaits the company’s next earnings update.

Fact box

Company: Straumann Holding AG
ISIN: CH0012280076
Ticker: not specified in available data
Exchange: SIX Swiss Exchange
Price (as of August 25, 2026): CHF 92.00
Market cap: CHF 14,813 million (as of August 25, 2026)
Sector / Industry: Medical instruments and supplies